Meiyou Technology
酶有科技
Meiyou Technology (酶有科技) is a Chinese biotech startup founded in March 2023 that develops enzymatic DNA synthesis technology, aiming to achieve *de novo* DNA synthesis at one-tenth the cost of conventional chemical methods. The company raised an angel round of tens of millions of RMB in 2024, led by Linear Capital with participation from MiraclePlus and Danen Capital, with proceeds directed toward experimental development, instrument R&D, and team building . The funding was reported by 36氪 in June 2024 .
elsewhere's corpus does not contain additional coverage of Meiyou Technology beyond this single funding announcement.
AI-generated — may contain errors, please verify.
Coverage
Taking Gems From Fire — Linear Capital's 2024 Year in Review
2024 is coming to a close. I'd like to borrow the theme from our annual meeting in October to summarize this year: *Taking Gems From Fire* — a fitting description of Linear Capital's work this past year.
Linear Capital | Linear Path, Nonlinear Growth
Striving to become China's best frontier tech and innovation fund.
AI Tech Drives Down Enzymatic DNA Synthesis Costs, Enzymo Technology Raises Tens of Millions in Angel Round Led by Linear Capital
Achieve de novo DNA synthesis at one-tenth the cost of chemical methods.
